Pennsylvania Medicaid MCO Prescription Drug Repricing: Cost Impacts of Using NADAC Payment Structure
November 14, 2019
Pennsylvania has proposed legislation (PA HB 941) to reconfigure the payment rates used for Medicaid prescriptions paid by Medicaid MCOs...
October 31, 2019
Most state Medicaid programs have predominantly transitioned the prescription drug benefit to the managed care setting, through which Medicaid managed...
July 11, 2019
A recent report from the Massachusetts Health Policy Commission used publicly available drug pricing data in an attempt to identify...
May 10, 2019
Recent reports from 46brooklyn Research and their consulting arm 3 Axis Advisors have used publicly available drug pricing data, and...
March 18, 2019
Senior voters with Part D plans have largely not heard about proposed changes to Part D, however, and will punish...
February 26, 2019
Increasing Drug List Prices Show No Correlation with Change in Rebates (2012–2017) View the Infographic Major Findings: Increasing list prices...
Medicare Part B Price Increases
February 25, 2019
See Infographic on prescription drug price increases in Medicare Part B...
Increased Costs Associated With Proposed State Legislation Impacting PBM Tools
January 10, 2019
Visante was commissioned by the Pharmaceutical Care Management Association (PCMA) to estimate the potential cost impact of four types of...
Visante: Reconsidering Drug Prices, Rebates, and PBMs
August 15, 2018
The Visante study highlights top selling Medicare Part D brand-name drugs with steady price increases and no change in rebate...
PCMA Comments on Administration’s Blueprint on Drug Pricing
July 16, 2018
Click here to read PCMA’s comments on the Blueprint...
Oliver Wyman Study: Premium Impact of Removing Manufacturer Rebates from the Medicare Part D Program
July 16, 2018
In 2018, more than 44 million seniors and people with disabilities are expected to be enrolled in Medicare Part D....
Legal Analysis: Antitrust Considerations of Proposals to Limit Rebates
July 15, 2018
A legal analysis raises significant concerns as to drug manufacturers’ ability to offer upfront discounts under current antitrust case law....